IRIS
IZZO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.337
EU - Europa 1.299
SA - Sud America 609
AS - Asia 339
AF - Africa 19
OC - Oceania 2
Totale 3.605
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.161
IT - Italia 822
BR - Brasile 423
SG - Singapore 199
MX - Messico 139
UA - Ucraina 134
CN - Cina 110
NL - Olanda 97
DE - Germania 56
CO - Colombia 54
FI - Finlandia 47
EC - Ecuador 41
IE - Irlanda 37
ES - Italia 25
PE - Perù 25
CA - Canada 23
AR - Argentina 22
BO - Bolivia 21
FR - Francia 21
GB - Regno Unito 21
CI - Costa d'Avorio 16
CL - Cile 15
SE - Svezia 13
VN - Vietnam 12
CH - Svizzera 9
IN - India 8
VE - Venezuela 6
PT - Portogallo 5
CR - Costa Rica 4
HN - Honduras 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
IR - Iran 3
KR - Corea 3
RO - Romania 3
AU - Australia 2
JP - Giappone 2
UY - Uruguay 2
BE - Belgio 1
DK - Danimarca 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
PA - Panama 1
PK - Pakistan 1
RU - Federazione Russa 1
SV - El Salvador 1
VA - Santa Sede (Città del Vaticano) 1
Totale 3.605
Salva come PNG Salva come JPEG
Città #
Chandler 176
Singapore 171
Amsterdam 95
Napoli 80
Ashburn 68
Jacksonville 67
Naples 65
Millbury 52
Princeton 44
Rome 40
Beijing 38
Santa Clara 33
Milan 32
Boston 31
Nanjing 28
Des Moines 24
Lima 22
Quito 22
Mexico 21
São Paulo 21
Woodbridge 20
Ottawa 19
Medellín 18
Wilmington 17
La Paz 16
Bogotá 12
Dong Ket 12
Santiago 12
Bari 11
Falls Church 11
Shenyang 11
Cuenca 10
Lawrence 10
Salerno 10
Brasília 9
Caserta 9
Fortaleza 9
Salvador 9
Hebei 8
Nanchang 8
Seattle 8
Genova 7
Tijuana 7
Buenos Aires 6
Kronberg 6
Monterrey 6
Palmi 6
Veracruz 6
Belo Horizonte 5
Brescia 5
Florence 5
Houston 5
Mendoza 5
Munich 5
Redwood City 5
Rio De Janeiro 5
Santa Cruz 5
Verona 5
Campo Grande 4
Federal 4
Feira De Santana 4
Guadalajara 4
Göttingen 4
Illac 4
Jiaxing 4
Lappeenranta 4
Madrid 4
Mantova 4
Menlo Park 4
Messina 4
Palermo 4
Saint-cyprien 4
São Luís 4
Addis Ababa 3
Bauru 3
Bologna 3
Bordeaux 3
Brindisi 3
Caracas 3
Cascina 3
Casoria 3
Castel San Giorgio 3
Cuauhtémoc 3
Dallas 3
Dublin 3
Ercolano 3
Guarujá 3
Guayaquil 3
Hidalgo 3
Manaus 3
Montecchio Maggiore 3
Morciano di Romagna 3
Mountain View 3
Natal 3
Pisa 3
Portici 3
Pune 3
Reggio Nell'emilia 3
Santo Domingo 3
Siena 3
Totale 1.614
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.331
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 291
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 89
Laboratory medicine: health evaluation in elite athletes 76
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 67
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 62
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 59
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 58
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 53
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 52
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 52
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 50
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 50
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 49
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 48
Spleen is the dark side of essential Thrombocitemia 47
Molecular Analysis of Cluster Headache 47
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 46
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 46
SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods 46
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 45
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 45
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 45
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 43
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 43
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 42
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 42
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 40
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 38
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 38
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 38
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 38
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 38
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 36
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 36
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 34
Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry 34
Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe 33
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 32
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 32
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 31
Molecular monitoring in chronic myeloid leukemia (CML) 30
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale 29
MiR‐27a downregulates 14‐3‐3θ, RUNX1, AF4, and MLL‐AF4, crucial drivers of blast transformation in t(4;11) leukemia cells 25
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 25
Late appearance of t(8;14) with c-myc rearrangement and disappearance of JH rearrangement leading to aggressive progression in a case of low grade non Hodgkin’s lymphoma” 25
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition 24
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 24
Droplet digital pcr for bcr–abl1 monitoring in diagnostic routine: Ready to start? 23
Wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes 22
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study 21
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 21
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. 19
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study 19
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 18
Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia 13
Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical bcr-abl1 transcripts 12
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype 11
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche 10
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy 9
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 9
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 4
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches 3
Totale 3.818
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.926
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.926
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020134 0 0 0 0 14 21 2 9 3 8 42 35
2020/2021261 14 23 23 30 31 35 25 4 24 16 19 17
2021/2022444 33 4 6 6 6 17 21 17 51 28 140 115
2022/2023497 58 29 19 17 57 53 3 57 71 92 32 9
2023/2024361 17 50 71 17 22 52 12 41 8 9 45 17
2024/2025313 94 97 15 54 53 0 0 0 0 0 0 0
Totale 3.818